inRegen, is a biotechnology company focused on developing advanced cellular therapies for treating chronic kidney disease (CKD).  Our technology is based on over 14 years of proprietary breakthroughs in progenitor cell biology research, development and manufacturing. inRegen produces a personalized autologous cell therapy, by using the patient's own cells and proprietary methods of manufacturing.  Since ReACT is made of the patient's own cells, there is no risk of rejection and no need for lifelong immunosuppressive therapy as is required in transplantation.